Price Target Analysis of Antares Pharma, Inc.(NASDAQ:ATRS): B2Gold Corp(NYSE:BTG)

0
5

Antares Pharma, Inc. (ATRS) will report its next earnings on Mar 12 BMO. The company reported the earnings of $0.04/Share in the last quarter where the estimated EPS by analysts was $-0.02/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 300%.

Many analysts are providing their Estimated Earnings analysis for Antares Pharma, Inc. and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $-0.04/share. These analysts have also projected a Low Estimate of $-0.06/share and a High Estimate of $-0.02/share.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for Antares Pharma, Inc. as 18.18 Million. According to these analysts, the Low Revenue Estimate for Antares Pharma, Inc. is 16.59 Million and the High Revenue Estimate is 19.62 Million. The company had Year Ago Sales of 12.7 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for ATRS to be 0%. They are projecting Next Quarter growth of 0%. For the next 5 years, Antares Pharma, Inc. is expecting Growth of 1492.86% per annum, whereas in the past 5 years the growth was 50% per annum.

Some buy side analysts are also providing their Analysis on Antares Pharma, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Antares Pharma, Inc. might touch $8 high while the Average Price Target and Low price Target is $6.15 and $4.5 respectively.

Antares Pharma, Inc. closed its last trading session at $2.89 with the loss of -1.73%. The Market Capitalization of the company stands at 433.16 Million. The Company has 52-week high of $3.96 and 52-week low of $2.16. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -8.22% where SMA50 and SMA200 are -13.34% and -10.78% respectively. The Company Touched its 52-Week High on 03/04/19 and 52-Week Low on 05/08/18.

The Relative Volume of the company is 1.01 and Average Volume (3 months) is 1.01 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 10.14.

The company shows its Return on Assets (ROA) value of -8.5%. The Return on Equity (ROE) value stands at -22.4%. While it’s Return on Investment (ROI) value is -25.9%.

While looking at the Stock’s Performance, Antares Pharma, Inc. currently shows a Weekly Performance of -5.65%, where Monthly Performance is -21.33%, Quarterly performance is -8.68%, 6 Months performance is -15.73% and yearly performance percentage is 20.34%. Year to Date performance value (YTD perf) value is 4.41%. The Stock currently has a Weekly Volatility of 4.43% and Monthly Volatility of 4.94%.

Many analysts are providing their Estimated Earnings analysis for B2Gold Corp and for the current quarter 12 analysts have projected that the stock could give an Average Earnings estimate of $0.02/share. These analysts have also projected a Low Estimate of $-0.01/share and a High Estimate of $0.07/share.

In case of Revenue Estimates, 4 analysts have provided their consensus Average Revenue Estimates for B2Gold Corp as 204.25 Million. According to these analysts, the Low Revenue Estimate for B2Gold Corp is 174 Million and the High Revenue Estimate is 263 Million. The company had Year Ago Sales of 181.19 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for BTG to be -50%. They are projecting Next Quarter growth of -20%. For the next 5 years, B2Gold Corp is expecting Growth of 34.31% per annum, whereas in the past 5 years the growth was 6.25% per annum.

Some buy side analysts are also providing their Analysis on B2Gold Corp, where 10 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for B2Gold Corp might touch $6.75 high while the Average Price Target and Low price Target is $5.21 and $4.25 respectively.

B2Gold Corp closed its last trading session at $2.75 with the gain of 0.36%. The Market Capitalization of the company stands at 2.73 Billion. The Company has 52-week high of $3.35 and 52-week low of $2.10. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -2.34% where SMA50 and SMA200 are -7.44% and 4.14% respectively. The Company Touched its 52-Week High on 02/22/19 and 52-Week Low on 08/16/18.

The Relative Volume of the company is 0.57 and Average Volume (3 months) is 4.75 million. The company’s P/E (price to earnings) ratio is 162.35 and Forward P/E ratio of 13.14.

The company shows its Return on Assets (ROA) value of 0%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, B2Gold Corp currently shows a Weekly Performance of -1.43%, where Monthly Performance is -4.5%, Quarterly performance is -3.5%, 6 Months performance is 13.58% and yearly performance percentage is -4.5%. Year to Date performance value (YTD perf) value is -5.48%. The Stock currently has a Weekly Volatility of 3.62% and Monthly Volatility of 3.64%.

SHARE